Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II of FLAG-Ida With Venetoclax and Asciminib in CML and Ph+ AML
NCT07604233Phase 2Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2026
- Primary completion
- Jun 2031
- Countries
- 1
01
Overview
A Phase 2 trial of asciminib in chronic myeloid leukemia (CML), acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
asciminib
03
Conditions
chronic myeloid leukemia (CML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07604233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07604233.